US 11,998,533 B2
Pharmaceutical compositions comprising LTV-17 and beta-lactamase inhibitors and their use as antibacterial agents
Sameeh M. Salama, Edmonton (CA); Samarendra N. Maiti, Edmonton (CA); and Renata Jankowska, Edmonton (CA)
Assigned to FEDORA PHARMACEUTICALS INC., Edmonton (CA)
Filed by FEDORA PHARMACEUTICALS INC., Edmonton (CA)
Filed on Nov. 10, 2022, as Appl. No. 17/984,553.
Claims priority of provisional application 63/263,963, filed on Nov. 12, 2021.
Prior Publication US 2023/0149368 A1, May 18, 2023
Int. Cl. A61K 31/427 (2006.01); A61K 31/4188 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/427 (2013.01) [A61K 31/4188 (2013.01); A61P 31/04 (2018.01)] 14 Claims
 
1. A synergistic pharmaceutical combination comprising compound LTV-17 (I) or a pharmaceutically acceptable salt thereof, solvate thereof, or solvate of the salt thereof:

OG Complex Work Unit Chemistry
and one or more β-lactamase inhibitor or a pharmaceutically acceptable salt thereof or a biologically hydrolysable prodrug thereof.